Sun Pharmaceutical Industries and its Taro Pharmaceuticals U.S.A. subsidiary are paying $200 million to resolve claims that they took part in a price-fixing scheme affecting generic drugs.
The money goes to consumers and insurers who indirectly bought the affected drugs, under a settlement that has already received final court approval. The deal covers "end-payers" — people and third-party payers who paid for the drugs without buying them straight from the manufacturer, as Bloomberg reported when the settlement was announced in July 2025. Sun and Taro did not admit wrongdoing as part of the agreement.
Official resources:
- Explore the official data from SEC — Use this primary source to review the underlying data.
- Read the original report from Mlex — Use this primary source to review the complete report.
Table of Contents
- What this settlement is and where it came from
- Who qualifies for a payment
- How this relates to the earlier direct-purchaser settlement
- What stayed outside the settlement
- Filing a claim
- Frequently Asked Questions
What this settlement is and where it came from
The $200 million settlement resolves end-payer claims in the generic-drug price-fixing multidistrict litigation pending in the U.S. District Court for the Eastern District of Pennsylvania, according to Bloomberg. That litigation consolidates lawsuits accusing generic-drug manufacturers of coordinating to keep prices artificially high rather than competing on price. FiercePharma reported that the agreement, announced in July 2025, specifically resolves claims brought by end-purchasers — consumers and third-party payers, such as insurers, who bought the companies' generic drugs indirectly rather than straight from the manufacturer.
At the time it was announced, the deal still needed court approval before any money could move toward claimants. That approval has since arrived. Judge Cynthia M. Rufe of the Eastern District of Pennsylvania granted final approval of the $200 million settlement on January 23, 2026, clearing the way for the fund to be distributed to the class, according to Bloomberg Law. MLex independently confirmed the same ruling.
Who qualifies for a payment
According to a legal settlement-tracking site, RecordingLaw.com, verified July 16, 2026, eligible claimants are consumers and third-party payers who indirectly purchased or reimbursed certain named generic drugs between May 1, 2009 and December 31, 2019. Geographic eligibility is broad but not universal. The same source states the class covers any U.S. state except Indiana and Ohio, plus Washington, D.C., Puerto Rico and the U.S.
Virgin Islands. That means residents of most states who paid for the covered drugs during that decade-long window, whether out of pocket or through an insurer that passed costs along, fall within the class as described. Two groups sit outside this particular settlement. Direct purchasers — companies that bought the drugs straight from Sun or Taro, such as wholesalers or large pharmacy chains — were covered by a separate, earlier settlement (see Section 3). State attorneys general also pursued their own claims against Sun and Taro, and those claims were kept out of the end-payer release.
How this relates to the earlier direct-purchaser settlement
This $200 million deal is not the first settlement Sun and Taro reached in the generic-drug pricing litigation. It is separate from, and additional to, an earlier settlement with direct purchasers in the same MDL, finally approved by the court on March 9, 2023, according to a court order posted by Cohen Milstein. That direct-purchaser settlement was originally agreed at $85 million but was reduced to $75 million after some class members opted out rather than participate.
Taro's own disclosure corroborates the reduction: the company's Form 20-F for fiscal year 2023, filed with the SEC, states it paid roughly $67.6 million of that settlement, cut by about $7.96 million for opt-outs. Together, the two settlements show Sun and Taro paying out on two separate tracks of the same underlying price-fixing allegations — one for companies that bought directly, another for the much larger pool of consumers and payers who bought indirectly. A claimant's position in the supply chain determines which settlement, if either, applies to them.
What stayed outside the settlement
Final approval of the end-payer deal did not close out every legal action against Sun and Taro arising from the same conduct. The January 23, 2026 final-approval order again excluded state attorneys general's own claims from the release, according to Law360, after the AGs asked the court in a December 2025 filing to keep their separate action untouched by the settlement.
That means state attorneys general can continue to pursue their own case against Sun and Taro independently of the $200 million fund now being distributed to end-payer claimants. A consumer or payer who receives money from this settlement is not affected by how that separate state action proceeds, since it runs on its own track.
Filing a claim
A settlement-tracking site states the claim-form deadline is November 9, 2026, with payouts distributed on a pro-rata basis — meaning each valid claimant's share depends on the total number of valid claims filed, not a fixed dollar amount per person, according to RecordingLaw.com. No court filing or official settlement-administrator page was located directly confirming that November 9, 2026 deadline or the exact claim-filing mechanics.
Because that date currently rests on secondary settlement-tracking sources rather than a primary filing, anyone preparing to file should verify the deadline and submission process against the Eastern District of Pennsylvania's docket for the generic-drug pricing MDL before relying on it. Claimants preparing to file should have documentation ready connecting their purchases to the May 1, 2009 through December 31, 2019 window the tracking site describes, since a pro-rata fund rewards claims that are complete and verifiable the first time.
Frequently Asked Questions
Does this settlement cover people who bought generics directly from Sun or Taro?
No. Direct purchasers were covered by a separate settlement, finally approved on March 9, 2023 at a reduced $75 million, according to the Cohen Milstein court order. This $200 million deal is for end-payers only.
Is the $200 million settlement final, or could it still change?
Judge Cynthia M. Rufe granted final approval on January 23, 2026, according to Bloomberg Law, so the fund is cleared for distribution to the class.
Are state attorneys general claims part of this payout?
No. The final-approval order excluded state AG claims from the release, per Law360, so that litigation continues separately.